News

Gilead Science's fixed-dose combination of bictegravir and emtricitabine/tenofovir alafenamide has been granted an NDA for the treatment of HIV infection.

Could US leaders in government and health care follow the same route?

In a 600-patient study, PCPs and NPs were shown to be just as effective as specialists in HCV treatment with direct-acting antivirals.

A meta-analysis of 9 studies found that water-based exercise is an equal alternative for type 2 diabetics.

Soldiers in army units where suicide attempts occured in the past year were more likely to attempt suicide themselves.

Within a week of a Presidential committee tasked with overseeing the epidemic, a study has shown national addiction drug death rates are understated.

Patients with diabetes, hypertension, and who smoked were found to be more likely to develop dementia, regardless of race.

A biomarker for pancreatic precursor cells might give researchers a shortcut to create insulin-producing beta cells that can be transplanted into patients with type 1 diabetes.

Evolocumab was shown to lower cardiovascular risk between 15 to 20% in a randomized, double-blind, placebo-controlled study.

Researchers reviewed the current trends in C. difficile treatment with vancomycin in order to shed light on the potential negative effects of cost-related medication non-adherence to vancomycin therapy patients.

FMT has a high cure rate and potentially lower cost compared to other C. difficile therapies. Specifically though, in children, such study results have not been published yet.

The hospital topped the list for the second straight year.

In the past decade, the number of individuals who receive solid organ transplants has increased exponentially – something that makes the peri-transplant complications like C. Difficile a common occurrence.

No Evidence of Disease Progression (NEDA) seems like a clear-cut designation for patients with relapsing-remitting multiple sclerosis, but a new study suggests it isn’t always as definitive as it sounds.

Researchers reviewed nearly 40 million commercially insured patients’ medical records in order to determine how quickly and in what proportions multiple recurrent C. difficile infection rates are growing ahead of C. difficile.

The FDA's FAERS analysis of canagliflozin has confirmed that its use "might be associated with an increased risk of amputations."

The FDA decision regarding Zelboraf’s approval for Erdheim-Chester disease with BRAF V6000 Mutations is expected by December 2017.

The drug is the first patient-friendly LINCL treatment of its kind and helps regulate Tripeptidyl Peptidase 1.

The drug reduced exacerbations and improved quality of life for patients who had symptoms despite treatment with corticosteroids and long-acting bronchodilators.

A group of patients following resistance training improved thier cortical thickness and MS Functional Composite score by trial's end.

The injunction stands until the company complies with FD&C Act regulations.

A statistically significant proportion of patients were migraine-free 2 hours after taking lasmiditan versus placebo.

A majority patients over 65 years old studied suffered a worse quality of life when told informed of their diagnoses.

The CDC-based study sought to combat influenza epidemic risks with an earlier jump on outbreak detection.

They suffer higher rates of morbidity and mortality from asthma, but their response to treatment and underlying physiological conditions are not as well known.

Comparison of 6 HARMONY trials showed that albiglutide not only treats type 2 diabetes as effectively as current methods but may reduce the burden felt by other injection-based treatments.

Higher levels of nighttime noise exposure during the first trimester showed correlation with a risk for GDM.

The cost-effectiveness of curing hepatitis C virus relative to managing the chronic illness has been argued, and now pharmacoeconomic comparisons may have identified the most cost-effective treatment regimen.

The investigational hepatitis-B drug has been rejected for approval twice in the past 3 years, but creator Dynavax Technologies still hopes for an early 2018 US commercial release.

The fixed-dose combination therapy is an 8-week, once-daily treatment option for all HCV genotype diagnoses.